CCL25 Protein (AA 24-150)

Catalog No. ABIN2666903

This Recombinant CCL25 protein is expressed in Escherichia coli (E. coli).

Quick Overview for CCL25 Protein (AA 24-150) (ABIN2666903)

Target: CCL25 (Chemokine (C-C Motif) Ligand 25 (CCL25))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 24-150

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Bioactivity was measured by its property to chemoattract BaF3-hCCR9 transfectants in a dose dependent manner.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: CCL25 (Chemokine (C-C Motif) Ligand 25 (CCL25))

Alternative Name: CCL25

Background: CCL25 (TECK) binds to CCR9, the only known receptor for TECK. CCR9 is expressed by a small population of circulating memory CD4+ and CD8+ lymphocytes expressing the intestinal homing receptor α4β7. Therefore, CCL25 is a key regulator for CCR9+CD4+ α4β7 T cell homing to the small intestine. In addition, CCL25 induces adhesion of CD103+ (αEβ7) on CD8 intraepithelial lymphocytes to its epithelial ligand E-cadherin. In inflammatory bowel diseases (IBD), as in celiac and Crohn's diseases, the proportion of CCR9+ cells in the peripheral blood and in the gut seems to be inversed, there is a lower frequency of CCR9+CD4+ T cells in the gut mucosa than in the peripheral blood. Also, a decrease in CCR9+CD4+ T cells occurs in the gut of HIV-infected patients. This decrease correlates with a lower expression of CCL25 by inflamed gut endothelial cells. Unusual expression of CCL25 in the liver occurs in primary sclerosis cholangitis (extra-intestinal complication of IBD). In this way, human T cells activated in the gut can be recruited to liver endothelium. Functional expression of CCR9 has been detected in melanoma derived cells, and it has been associated to small intestine metastatic melanoma processes. In addition, CCR9 is expressed by ovarian, breast, and prostate cancer cells.

Molecular Weight: The 128 amino acid recombinant protein has a predicted molecular mass of approximately 14.3 kDa. The DTT-reduced and non-reduced protein migrate at approximately 16 and 17 kDa by SDS-PAGE respectively. The N-terminal amino acid is Met.